Peter Hertel
Overview
Explore the profile of Peter Hertel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kane J, Kinon B, Forray C, Such P, Mittoux A, Lemming O, et al.
Schizophr Res
. 2022 Sep;
248:271-278.
PMID: 36115192
Introduction: Treatment resistance constitutes the highest burden of disease within schizophrenia. We hypothesized that the synergistic activity of Lu AF35700 at dopamine D and D receptors might provide superior antipsychotic...
2.
Calabrese J, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al.
J Affect Disord
. 2018 Aug;
241:425-432.
PMID: 30145513
Background: Aripiprazole once-monthly 400 mg (AOM 400), an atypical long-acting injectable antipsychotic, has demonstrated efficacy and safety in maintenance treatment of bipolar I disorder (BP-I). We further assess safety and...
3.
Calabrese J, Jin N, Johnson B, Such P, Baker R, Madera J, et al.
Int J Bipolar Disord
. 2018 Jun;
6(1):14.
PMID: 29886522
Background: The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate...
4.
Calabrese J, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al.
J Affect Disord
. 2017 Nov;
227:649-656.
PMID: 29174738
Background: Effects of maintenance treatment with aripiprazole once-monthly 400mg (AOM 400) on symptoms and functioning were assessed in adults with bipolar I disorder (BP-I) after a manic episode. Methods: Patients...
5.
Potkin S, Loze J, Forray C, Baker R, Sapin C, Peters-Strickland T, et al.
PLoS One
. 2017 Aug;
12(8):e0183475.
PMID: 28837593
Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between...
6.
Naber D, Baker R, Eramo A, Forray C, Hansen K, Sapin C, et al.
Schizophr Res
. 2017 Apr;
192:205-210.
PMID: 28433498
Objective: To evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400mg (AOM 400) in patients with schizophrenia. Methods: Patients who completed the QUALIFY study (NCT01795547) in the...
7.
Ismail Z, Peters-Strickland T, Miguelez M, Baker R, Hertel P, Eramo A, et al.
J Clin Psychopharmacol
. 2017 Apr;
37(3):347-350.
PMID: 28383362
Background: Long-acting injectable antipsychotics are treatment options for acute and long-term treatment of patients with schizophrenia. In a previously published 12-week randomized, double-blind, placebo-controlled clinical trial of patients with schizophrenia...
8.
Potkin S, Loze J, Forray C, Baker R, Sapin C, Peters-Strickland T, et al.
Int Clin Psychopharmacol
. 2017 Mar;
32(3):147-154.
PMID: 28252452
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM...
9.
Raoufinia A, Peters-Strickland T, Nylander A, Baker R, Eramo A, Jin N, et al.
Int J Neuropsychopharmacol
. 2017 Feb;
20(4):295-304.
PMID: 28204607
Background: Two open-label, randomized, parallel-arm studies compared pharmacokinetics, safety, and tolerability of aripiprazole once-monthly 400 mg following deltoid vs gluteal injection in patients with schizophrenia. Methods: In the single-dose study,...
10.
Calabrese J, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al.
J Clin Psychiatry
. 2017 Feb;
78(3):324-331.
PMID: 28146613
Objective: To evaluate efficacy, safety, and tolerability of long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) as maintenance treatment for bipolar I disorder (BP-I). Methods: In a double-blind, placebo-controlled,...